In vitro DNA synthesis in freshly separated human breast cancer cells assessed by tritiated thymidine incorporation assay: Relationship to the long-term outcome of patients

British Journal of Surgery

Volumn 86, Issue 11, 1999, Pages 1463-1469

  Nio, Y ^a   Tamura, K ^a   Kan, N ^d   Inamoto, T ^b   Ohgaki, K ^c   Kodama, H ^d  

^a SHIMANE UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Kyoto Police Hospital   (Japan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CARBOQUONE; CARMOFUR; CELL DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FLUOROURIDINE; MEDROXYPROGESTERONE; MITOMYCIN C; TAMOXIFEN; TEGAFUR; THYMIDINE; TRITIUM; UFT; URACIL;

ADULT; AGED; ARTICLE; BIOASSAY; BREAST CANCER; CANCER CELL; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CORRELATION FUNCTION; DNA SYNTHESIS; FEMALE; FOLLOW UP; HISTOLOGY; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0032747937     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1999.01248.x     Document Type: Article

References (25)

1. 1 Gershon-Cohen J, Berger SM, Klickstein HS. Roentgenography of breast cancer moderating concept of 'biologic predeterminism'. Cancer 1963; 16: 961-4.
2. 2 Spratt JS Jr, Spratt TL. Rates of growth of pulmonary metastases and host survival. Ann Surg 1964; 159: 161-71.
3. 3 Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. American Journal of Roentgenology, Radium Therapy and Nuclear Medicine 1956; 76: 988-1000.
4. 4 Kusama S, Spratt JS Jr, Donegan WL, Watson FR, Cunningham C. The gross rates of growth of human mammary carcinoma. Cancer 1972; 30: 594-9.
5. 5 Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24 740 breast cancer cases. Cancer 1989; 63: 181-7.
6. 6 Fisher B, Redmond C, Fisher ER, Caplan R, other contributing National Surgical Adjuvant Breast and Bowel Project Investigators. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients. J Clin Oncol 1988; 6: 1076-87.
7. 7 Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediciton of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320: 627-33.
8. 8 Fisher B, Gunduz N, Costantino J, Fisher ER, Redmond C, Mamounas EP et al. DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer 1991; 68: 1465-75.
9. 9 Haffty BG, Toth M, Flynn S, Fisher D, Carter D. Prognostic value of DNA flow cytometry in the locally recurrent, conservatively treated breast cancer patient. J Clin Oncol 1992; 10: 1839-47.
10. 10 Lipponen P, Papinaho S, Eskelinen M, Klemi PJ, Aaltomaa S, Kosma VM et al. DNA ploidy, S-phase fraction and mitotic indices as prognostic predictors of female breast cancer. Anticancer Res 1992; 12: 1533-8.
11. 11 Tubiana M, Pejovic MH, Koscielny S, Chavaudra N, Malaise E. Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 1989; 44: 17-22.
12. 12 Brifford M, Spyratos F, Tubiana-Hulin M, Pallud C, Mayras C, Filleul A et al. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cytomorphologic changes, initial tumor ploidy, and tumor regression. Cancer 1989; 63: 631-7.
13. 13 Remvikos Y, Beuzoboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 1989; 81: 1383-7.
14. 14 Gamel JW, Meyer LS, Province MA. Proliferative rate of S-phase measurement may affect cure of breast carcinoma. Cancer 1995; 76: 1009-18.
15. 15 Hermanek P, Sobin LH, eds. TNM Classification of Malignant Tumours. 4th, fully revised ed. Berlin: Springer, 1987.
16. 16 Nio Y, Imai S, Shiraishi T, Tsubono M, Morimoto H, Tseng CC et al. Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay. Cancer 1990; 65: 1273-8.
17. 17 Nio Y, Tamura K, Tsubono M, Kawabata K, Masai Y, Hayashi H et al. Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay. Ann Surg 1995; 221: 89-99.
18. 18 Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22 616 cases of breast cancer. The basis for a prognostic index. Cancer 1991; 68: 2142-9.
19. 19 Henson DE, Fielding LP, Grignon DJ, Page DL, Hammond ME, Nash G et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Arch Pathol Lab Med 1995; 119: 1109-12.
20. 20 Kubota Y, Hosaka M, Fukushima S, Kondo I. Prophylactic oral UFT therapy for superficial bladder cancer. Cancer 1993; 71: 1842-5.
21. 21 Arima S, Ohsato K, Hisatsugu T, Shimura H. Multicentre randomised study of adjuvant chemotherapy with mitomycin C and tegafur or tegafur-uracil in gastric cancer. Eur J Surg 1994; 160: 227-32.
22. 22 Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol 1995; 21: 69-71.
23. 23 Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296-300.
24. 24 Saltz LB, Leichman C, Young CW, Muggia FM, Conti JA, Spiess T et al. A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995; 75: 782-5.
25. 25 Silverstrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 1995; 13: 697-704.